China Approves Amgen's Lung Cancer Drug Tarlatamab

• Tarlatamab targets hard-to-treat small cell lung cancer in adults at the extensive stage after chemotherapy failure
• Wall Street analysts estimate the drug could generate over $2 billion in annual sales for Amgen
• Launch date and pricing for the Chinese market have not been disclosed by Amgen or Hong Kong-listed partner BeOne Medicines

Summary

Key Development:

China's National Medical Products Administration has approved Amgen's lung cancer drug tarlatamab, marking a significant expansion into the Chinese market. The announcement was made on April 10 by BeOne Medicines, Amgen's development and commercialization partner in the region.

Drug Details:

Tarlatamab is a targeted immunotherapy designed for adults with extensive-stage small cell lung cancer whose condition has progressed despite chemotherapy. The drug is part of Amgen's bispecific antibody pipeline, engineered to connect cancer cells with immune cells, enabling the body's immune system to eliminate cancerous tissue. In the U.S. market, Amgen markets the drug under the brand name Imdelltra.

Companies Involved:

• Amgen: U.S.-based biopharmaceutical company and drug developer
• BeOne Medicines: Hong Kong-listed partner handling development and commercialization in China

Financial Implications:

Wall Street analysts project tarlatamab could generate over $2 billion in annual sales for Amgen, representing a substantial revenue opportunity. The Chinese approval expands this potential by accessing one of the world's largest pharmaceutical markets.

Outstanding Information:

Neither Amgen nor BeOne Medicines provided details on the drug's launch date or pricing strategy for the Chinese market, leaving key commercial questions unanswered.

Market Context:

The approval addresses a significant unmet medical need in treating hard-to-treat small cell lung cancer, a particularly aggressive form of the disease with limited treatment options after chemotherapy failure.